Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
c19early.org COVID-19 treatment researchAzvudineAzvudine (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

 
    
  
Azvudine for COVID-19
27 studies from 323 scientists
29,199 patients in 2 countries
Significantly lower risk for mortality, progression, and viral clearance.
20 studies from 17 independent teams in 2 countries show significant benefit.
COVID-19 Azvudine studies. Dec 2024. c19early.org
0 0.5 1 1.5+ All studies 29% With exclusions 31% Mortality 31% Hospitalization 6% Recovery 6% Viral clearance 13% RCTs 27% Early 37% Late 29% Favorsazvudine Favorscontrol
Home   Post   Share   @CovidAnalysis   Meta AnalysisMeta   Azvudine is a nucleoside reverse transcriptase inhibitor (NRTI), designed to interfere with the replication of RNA viruses. Azvudine targets the viral RNA-dependent RNA polymerase (RdRp), a critical enzyme that SARS-CoV-2 uses to replicate its RNA genome. Azvudine was originally developed for other viral diseases, such as HIV and hepatitis. Recent:
Zhu
Zhang
Ren
Xu
Li
Zhang.
Azvudine was adopted in 1 country. Submit updates/corrections. Summary.
Dec 23
Covid Analysis Azvudine reduces COVID-19 risk: real-time meta analysis of 27 studies
Significantly lower risk is seen for mortality, progression, and viral clearance. 20 studies from 17 independent teams in 2 countries show significant benefit. Meta analysis using the most serious outcome reported shows 29% [18‑..
Dec 12
Zhu et al., Acta Pharmaceutica Sinica B, doi:10.1016/j.apsb.2024.12.004 Real-world efficacy and safety of azvudine in hospitalized older patients with COVID-19 during the omicron wave in China: A retrospective cohort study
22% lower mortality (p=0.001), 13% higher hospital discharge (p=0.05), 1% shorter hospitalization (p=0.43), and 10% faster viral clearance (p<0.0001). PSM retrospective 3,998 hospitalized COVID-19 patients aged 60 years and older in China showing lower all-cause mortality, higher rate of discharge, and shorter time to viral clearance with azvudine treatment.
Nov 22
Zhang et al., Frontiers in Cellular and Infection Microbiology, doi:10.3389/fcimb.2024.1390098 Efficacy of azvudine plus dexamethasone in severe hospitalized patients with Omicron infection: a prospective multicenter study
43% lower progression (p=0.03) and 14% faster viral clearance (p=0.02). Prospective multicenter study of 209 severe hospitalized COVID-19 patients in China showing improved 28-day composite outcomes, faster viral clearance, and higher PaO2/FiO2 levels with azvudine plus dexamethasone compared to dexamethasone..
Nov 17
Ren et al., Journal of Infection, doi:10.1016/j.jinf.2024.106355 Real-world effectiveness and safety of Azvudine in hospitalized patients with SARS-CoV-2 infection: a multicenter, retrospective cohort study
32% lower mortality (p<0.0001) and 12% lower progression (p=0.01). PSM retrospective 32,864 hospitalized COVID-19 patients in China showing lower all-cause mortality and disease progression with azvudine treatment.
Nov 7
Xu et al., Frontiers in Cellular and Infection Microbiology, doi:10.3389/fcimb.2024.1453234 Systematic evaluation of therapeutic effectiveness of Azvudine in treating COVID-19 hospitalized patients: a retrospective cohort study
75% lower mortality (p=0.02) and 63% lower progression (p=0.02). Retrospective 264 hospitalized COVID-19 patients in China showing lower risk of composite disease progression and all-cause mortality with azvudine treatment.
Oct 7
Zhang et al., Infection and Drug Resistance, doi:10.2147/IDR.S481591 Efficacy of Azvudine Therapy in Patients with Severe and Non-Severe COVID‐19: A Propensity Score-Matched Analysis
32% higher mortality (p=0.2), 62% higher ventilation (p=0.22), 7% higher ICU admission (p=0.89), and 9% shorter hospitalization (p=0.05). PSM retrospective 303 hospitalized patients treated with azvudine and 303 matched controls in China, showing shorter hospital stay and higher lymphocyte improvement rate, particularly for non-severe patients, however there were no signifi..
Jul 31
Li et al., Chinese Chemical Letters, doi:10.1016/j.cclet.2024.110238 Azvudine alleviates SARS-CoV-2-induced inflammation by targeting myeloperoxidase in NETosis
In Silico, In Vitro, and rhesus macaque study showing that azvudine (FNC) alleviates SARS-CoV-2-induced inflammation by targeting myeloperoxidase (MPO) and reducing neutrophil extracellular trap (NET) formation. Authors demonstrated FNC's..
Jul 12
Dong et al., The Clinical Respiratory Journal, doi:10.1111/crj.13798 Efficacy and Safety of Azvudine in Patients With COVID‐19 in China: A Meta‐Analysis of Observational Studies
39% lower mortality (p<0.0001) and 33% lower progression (p=0.009). Meta analysis of 24 studies with 11,830 COVID-19 patients in China, showing significantly lower mortality, lower combined mortality/ventilation/ICU admission, and faster viral clearance with azvudine compared to SOC. In studies comparing ..
Jun 24
Lv et al., Journal of Zhejiang University - SCIENCE B (Biomedicine & Biotechnology, doi:10.1631/jzus.B2300538 Clinical characteristics and outcomes of hospitalized kidney transplant recipients with COVID-19 infection in China during the Omicron wave: a single-center cohort study
42% higher mortality (p=0.64). Retrospective 324 hospitalized kidney transplant recipients with COVID-19 showing no significant benefit with molnupiravir, paxlovid, or azvudine. The study was conducted during the omicron wave in China between December 2022 and January ..
Jun 13
Amani et al., PLOS ONE, doi:10.1371/journal.pone.0298772 Effectiveness and safety of azvudine in COVID-19: A systematic review and meta-analysis
52% lower mortality (p<0.0001), 10% lower ventilation (p=0.71), and 31% lower ICU admission (p=0.51). Meta analysis of 21 studies (7 studies have no control, comparing with paxlovid) with 10,011 COVID-19 patients showing lower mortality and faster viral clearance with azvudine treatment compared to standard of care or placebo, while there..
Apr 30
Liu et al., Infections in the immunosuppressed and immunocompromised host, doi:10.1164/ajrccm-conference.2024.209.1_MeetingAbstracts.A2917 Effectiveness of Azvudine and Nirmatrelvir-ritonavir in Kidney Transplant Recipients With COVID-19: A Retrospective Cohort Study
45% lower progression (p=0.36). Retrospective 148 hospitalized kidney transplant patients with COVID-19 in China showing lower risk of disease progression with azvudine treatment compared, and higher risk with paxlovid treatment.
Apr 1
Zhong et al., Research Square, doi:10.21203/rs.3.rs-4157424/v1 Azvudine reduces the mortality rate of patients with Coronavirus disease 2019: a single-center retrospective analysis study
35% lower mortality (p=0.05). Retrospective 2,862 hospitalized COVID-19 patients in China showing lower mortality with azvudine treatment.
Mar 27
Wu et al., Advanced Science, doi:10.1002/advs.202306050 Azvudine for the Treatment of COVID‐19 in Pre‐Existing Cardiovascular Diseases: A Single‐Center, Real‐World Experience
81% lower mortality (p=0.0008). Retrospective 351 hospitalized COVID-19 patients with pre-existing cardiovascular diseases in China, showing lower mortality with azvudine treatment.
Mar 4
Li et al., Journal of Cancer, doi:10.7150/jca.91530 A Retrospective Analysis of Azvudine in Patients with COVID-19 and Pre-existing Cancer
11% shorter hospitalization (p=0.26) and 50% improved viral clearance (p=0.03). PSM retrospective 84 hospitalized COVID-19 patients with pre-existing cancer in China, showing faster viral clearance with azvudine. There was no significant difference in length of hospital stay or ICU admission.
Feb 23
Wang et al., Virology Journal, doi:10.1186/s12985-024-02316-y Effectiveness of azvudine in reducing mortality of COVID-19 patients: a systematic review and meta-analysis
Systematic review and meta-analysis of 17 studies showing significantly lower mortality with azvudine compared to no antiviral treatment in COVID-19 patients. The mortality benefit was seen in both mild/moderate and severe disease, as wel..
Feb 12
Jin et al., Journal of Clinical Pharmacology and Therapeutics, 5:1 Effects of Azvudine on the Low-Risk Patients Infected with COVID-19 Omicron Variants: A Retrospective Case-Control Study
1% slower recovery (p=0.9). Retrospective 481 low-risk COVID-19 patients in China showing no significant difference in recovery or symptomatic severity with azvudine, but slightly lower total viral load.
Feb 9
Chen et al., Scientific Reports, doi:10.1038/s41598-024-53862-y Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study
Retrospective 157 hospitalized mild-to-moderate COVID-19 patients showing no significant differences between azvudine, molnupiravir, and paxlovid for time to viral clearance and length of hospitalization.
Feb 9
Wang et al., eClinicalMedicine, doi:10.1016/j.eclinm.2024.102468 Antiviral effectiveness and survival correlation of azvudine and nirmatrelvir/ritonavir in elderly severe patients with COVID-19: a retrospective real-world study
20% lower mortality (p=0.44) and 3% lower progression (p=0.91). Retrospective 249 elderly patients with severe COVID-19, 128 treated with azvudine, 66 treated with paxlovid, and 55 receiving neither treatment, showing no significant differences for Ct value changes, progression, or survival for either..
Jan 31
Peng et al., Technology in Cancer Research & Treatment, doi:10.1177/15330338241248573 Impact of Anti-angiogenic Drugs on Severity of COVID-19 in Patients with Non-Small Cell Lung Cancer
13% higher mortality (p=0.85). Retrospective 166 hospitalized NSCLC patients with COVID-19 showing no significant difference in mortality with paxlovid or azvudine in univariate analysis.
Jan 18
Zheng et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2024.107096 Small-molecule antivirals treatment for COVID-19: A systematic review and network meta-analysis
Systematic review and network meta-analysis of 160 studies involving over 900,000 COVID-19 patients assessing the efficacy and safety of small-molecule antivirals. For azvudine, significant benefits were found for mortality, mechanical ve..
Jan 5
Li et al., Research Square, doi:10.21203/rs.3.rs-3707560/v1 Risk of severe case in COVID-19 patients and Azvudine: A Retrospective cohort study after exit from ‘zero-COVID’ policy
29% lower mortality (p=0.03). Retrospective 4,201 hospitalized COVID-19 patients in China, showing lower mortality with azvudine.
Nov 7
2023
Zhao et al., Heliyon, doi:10.1016/j.heliyon.2023.e21941 Inflammatory predictors (eosinophil, C-RP and IL-6) and effectiveness of oral Azvudine tablets treatment in COVID-19 hospitalized patients: A retrospective, self-controlled study
Retrospective 60 hospitalized COVID-19 patients in China, 32 treated with azvudine for 7-14 days. The azvudine group had impoved eosinophil counts, CRP, IL-6, fibrinogen, NT-proBNP, and improved lung CT findings, suggesting reduced inflam..
Oct 21
2023
Liu et al., Heliyon, doi:10.1016/j.heliyon.2023.e21387 Clinical characteristics, outcomes, and risk factors of SARS-CoV-2 breakthrough infections among 572 fully vaccinated (BBIBP-CorV) hospitalized patients
24% lower progression (p=0.44). Retrospective 572 fully vaccinated hospitalized patients in China, showing lower risk with azvudine treatment, without statistical significance. The composite outcome included intubation, non-invasive respiratory support, ICU admission, a..
Oct 19
2023
de Souza et al., Frontiers in Medicine, doi:10.3389/fmed.2023.1215916 Phase III, randomized, double-blind, placebo-controlled clinical study: a study on the safety and clinical efficacy of AZVUDINE in moderate COVID-19 patients
82% improved recovery (p=0.01) and 13% faster viral clearance (p=0.03). RCT 179 hospitalized patients in Brazil, showing improved recovery with azvudine treatment.
Oct 13
2023
Wei et al., Frontiers in Pharmacology, doi:10.3389/fphar.2023.1274294 Head-to-head comparison of azvudine and nirmatrelvir/ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity score matching
no change in mortality (p=1), 28% lower ventilation (p=0.04), 55% lower ICU admission (p=0.05), and 22% lower progression (p=0.07). PSM retrospective 725 hospitalized COVID-19 patients in China compared the effectiveness and safety of the oral antivirals azvudine and paxlovid. There was no significant difference in the risk of disease progression between groups, but a..
Oct 12
2023
Zhou et al., Frontiers in Microbiology, doi:10.3389/fmicb.2023.1280026 Secondary pulmonary infection and co-infection in elderly COVID-19 patients during the pandemics in a tertiary general hospital in Beijing, China
22% lower mortality (p=0.15). Retrospective 322 hospitalized patients ≥65 in China, showing lower mortality with azvudine treatment, without statistical significance.
Sep 30
2023
Zhao et al., Infection and Drug Resistance, doi:10.2147/IDR.S423725 Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study
Retrospective propensity-matched analysis of 227 COVID-19 patients in Tibet, China comparing azvudine to paxlovid. Overall, azvudine had comparable viral clearance time and clinical outcomes to paxlovid. However, for mild COVID-19 cases, ..
Aug 31
2023
Dian et al., Journal of Infection, doi:10.1016/j.jinf.2023.05.012 Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities
64% lower mortality (p=0.11), 67% lower ventilation (p=0.28), and 48% lower progression (p=0.03). Retrospective 2,118 hospitalized COVID-19 patients in China, showing improved results with azvudine vs. paxlovid.
Aug 24
2023
Zhu, K., Frontiers in Pharmacology, doi:10.3389/fphar.2023.1228548 Efficacy and safety evaluation of Azvudine in the prospective treatment of COVID-19 based on four phase III clinical trials
Review of four phase III clinical trials evaluating the efficacy and safety of azvudine, a nucleoside analog, for the treatment of COVID-19. The trials were conducted in China, Russia, and Brazil on patients with mild to moderate disease...
Jul 23
2023
Shao et al., Microorganisms, doi:10.3390/microorganisms11071859 Composite Interventions on Outcomes of Severely and Critically Ill Patients with COVID-19 in Shanghai, China
56% lower mortality (p=0.007). Retrospective 1,082 severely and critically ill COVID-19 patients in China showing lower 60 day mortality with azvudine. Mortality was also lower with paxlovid, but without statistical significance, and health related quality of life was..
Jul 20
2023
Yang et al., Journal of Medical Virology, doi:10.1002/jmv.28947 Oral azvudine for mild‐to‐moderate COVID‐19 in high risk, nonhospitalized adults: Results of a real‐world study
91% lower mortality (p=0.09), 75% lower hospitalization (p=0.05), and 16% improved recovery (p=0.19). PSM retrospective 804 high-risk, nonhospitalized adults with mild to moderate COVID-19 in China. The study compared outcomes between 317 patients who received azvudine with 487 patients who received standard supportive treatment only. The..
Jul 14
2023
Han et al., Research Square, doi:10.21203/rs.3.rs-3145554/v1 Effectiveness and Optimal Timing of Azvudine in COVID-19 Patients: A Multi-center Retrospective Study in Beijing, China
37% lower mortality (p=0.05) and 3% greater improvement (p=0.73). PSM retrospective 6,218 hospitalized COVID-19 patients in China showing lower 28-day all-cause mortality with azvudine treatment compared to controls (HR 0.63, 95% CI 0.40-1.00). Subgroup analysis found significantly faster clinical impro..
Jul 13
2023
Zong et al., Acta Pharmaceutica Sinica B, doi:10.1016/j.apsb.2023.07.007 Azvudine reduces the in-hospital mortality of COVID-19 patients: A retrospective cohort study
62% lower mortality (p=0.0002). PSM retrospective 1072 hospitalized patients with COVID-19 pneumonia in China, showing lower mortality with azvudine treatment.
May 5
2023
Sun et al., eClinicalMedicine, doi:10.1016/j.eclinm.2023.101981 Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study
54% lower mortality (p=0.16), 38% lower need for oxygen therapy (p=0.15), and 48% lower progression (p=0.02). PSM retrospective 490 hospitalized COVID-19 patients with pre-existing conditions in China showing that azvudine was associated with a significantly lower risk of the composite outcome of disease progression, driven largely by lower rates..
Apr 30
2023
Chen et al., Cardiology Plus, doi:10.1097/CP9.0000000000000049 All-cause mortality in moderate and severe COVID-19 patients with myocardial injury receiving versus not receiving azvudine: a propensity score-matched analysis
6% lower mortality (p=0.88). PSM retrospective 332 hospitalized moderate to critically ill COVID-19 patients with myocardial injury in China, showing improved 14 day mortality but no difference in overall in-hospital mortality with azvudine treatment.
Jan 23
2023
Shen et al., medRxiv, doi:10.1101/2023.01.23.23284899 Real-world effectiveness of Azvudine in hospitalized patients with COVID-19: a retrospective cohort study
74% lower mortality (p=0.04), 91% lower ventilation (p=0.06), 75% lower ICU admission (p=0.37), and 57% lower progression (p=0.05). PSM retrospective 900 hospitalized COVID-19 patients in China showing lower risk of disease progression and death with azvudine treatment.
Jan 6
2023
Chen et al., medRxiv, doi:10.1101/2023.01.05.23284180 Oral Azvudine (FNC) Tablets in Patients infected with SARS-CoV-2 Omicron Variant: A Retrospective Cohort Study
12% slower recovery (p=0.95) and 32% improved viral clearance (p=0.04). Retrospective 207 COVID-19 patients in China, showing azvudine associated with faster viral clearance, with azvudine-treated patients obtaining a negative PCR test result 1.7 days faster on average compared to supportive care alone after ..
Dec 6
2021
Zhang et al., Signal Transduction and Targeted Therapy, doi:10.1038/s41392-021-00835-6 Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients
Analysis of azvudine (FNC) as a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients. Authors found that FNC inhibited SARS-CoV-2 and HCoV-OC43 coronavirus replication in vitro with EC50 between 1.2 and 4.3 μM. Oral ..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit